|
|
Expression and Clinical Significance of Muscarinic Acetylcholine Receptor M3 in Hilar Cholangiocarcinoma |
ZHANG Hongwei, WANG Cairu, MIAO Guodong, et al |
Chengde Central Hospital, Hebei Chengde 067000, China |
|
|
Abstract Objective: To investigate the expression of muscarinic acetylcholine receptor m3 (CHRM3) in hilar cholangiocarcinoma and its relationship with prognosis.Methods: A total of 69 cases of hilar cholangiocarcinoma and 69 cases of normal cholangiocarcinoma adjacent to cholangiocarcinoma resected by surgery in our hospital from January 2013 to April 2017 were selected as research objects. The expression of CHRM3 in hilar cholangiocarcinoma and paracancerous tissues was detected by immunohistochemistry, the relationship between the expression level of CHRM3 and the clinicopathological features of hilar cholangiocarcinoma were analyzed, and the relationship between the expression of CHRM3 and the prognosis of hilar cholangiocarcinoma was explored after follow-up for 3 years. Results: The positive rate of CHRM3 in the adjacent tissues and hilar cholangiocarcinoma was 7.25% and 84.06%, respectively; the difference was statistically significant (P<0.05). The expression level of CHRM3 in hilar cholangiocarcinoma was not related to age and gender (P>0.05), but related to pathological stage, pathological grade, lymph node metastasis and nerve infiltration (P<0.05). Kaplan-Meier method showed that the mean survival time of patients with CHRM3 negative hilar cholangiocarcinoma was (33.69 ± 0.76) months, which was significantly longer than (23.37 ± 1.02) months of CHRM3 positive patients (P<0.05). Multivariate analysis showed that nerve infiltration and positive CHRM3 were independent risk factors for poor prognosis in patients with hilar cholangiocarcinoma (P<0.05). Conclusions: The positive expression rate of CHRM3 in hilar cholangiocarcinoma is significantly increased, which is related to pathological stage, pathological grade, lymph node metastasis and nerve infiltration. The increased expression rate of CHRM3 is an independent risk factor for poor prognosis in hilar cholangiocarcinoma.
|
|
|
|
|
[1] 曹迪,李先亮,张荟,等.影响肝门部胆管癌术后远期预后的因素[J].首都医科大学学报,2020,41(3):439~443. [2] Detarya M,Sawanyawisuth K,Aphivatanasiri C,et al.The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling[J].Glycobiology,2020,30(5):312~324. [3] 范帅,赵伟,王国磊,等.ChRM3对胆管癌神经浸润的影响[J].精准医学杂志,2018,33(3):263~266. [4] 包志鹏,夏医君.肝门胆管癌诊断的研究进展[J].内蒙古医学杂志,2018,50(7):790~793. [5] 王文涛,杨闯,程南生,等.肝门部胆管癌切除术中右肝动脉重建技巧[J].中国普外基础与临床杂志,2018,25(7):779~780. [6] 王娱,颜洪竹,张伟,等.多巴胺受体与肿瘤的关系研究进展[J].转化医学杂志,2018,7(4):254~257. [7] Zheng C,Guan H,Liu Y,et al.Chemoenzymatically synthesized ganglioside GM3 analogues with inhibitory effects on tumor cell growth and migration[J].Eur Med Chem,2019,165(1):107~114. [8] Semenov I,Brenner R.Voltage effects on muscarinic acetylcholine receptor-mediated contractions of airway smooth muscle[J].Physiol Rep,2018,6(17):3856~3867. [9] Yu X,Riemekasten G,Petersen F.Autoantibodies against muscarinic acetylcholine receptor M3 in Sjogren's syndrome and corresponding mouse models[J].Front Biosci,2018,23(1):2053~2064. [10] Berndt-Paetz M,Herbst L,Weimann A,et al.IC/BPS-associated alterations of M2 and M3 muscarinic acetylcholine receptor trafficking in human detrusor[J].Neurourol Urodyn,2019,38(7):1818~1827. [11] Vasamsetti BMK,Liu Z,Park YS,et al.Muscarinic acetylcholine receptors regulate the dephosphorylation of eukaryotic translation elongation factor 2 in SNU-407 colon cancer cells[J].Arch Biochem Biophys,2019,516(2):424~429. [12] Felton J,Hu S,Raufman JP.Targeting M3 muscarinic receptors for colon cancer therapy[J].Curr Mol Pharmacol,2018,11(3):184~190. [13] 张亮,宦宏波,温旭东,等.毒蕈碱型胆碱能受体M3调控肝癌细胞侵袭转移的研究[J].第三军医大学学报,2017,39(6):509~514. [14] 张宏伟,王彩茹,缪国东,等.毒蕈碱型乙酰胆碱受体M3对胆管癌神经浸润的影响[J].临床检验杂志(电子版),2020,9(3):322~322. |
|
|
|